586 related articles for article (PubMed ID: 28104741)
1. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
2. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
4. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
Freudenberg LS; Jentzen W; Petrich T; Frömke C; Marlowe RJ; Heusner T; Brandau W; Knapp WH; Bockisch A
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2267-76. PubMed ID: 20661558
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
7. I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal.
Hong CM; Kim CY; Son SH; Jung JH; Lee CH; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
Ann Nucl Med; 2017 Oct; 31(8):582-589. PubMed ID: 28677070
[TBL] [Abstract][Full Text] [Related]
8. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract][Full Text] [Related]
10. Absorbed dose coefficients for adult thyroid cancer patients undergoing radioiodine therapy.
Kwon TE; Pasqual E; Kitahara CM; Lee C
J Radiol Prot; 2023 May; 43(2):. PubMed ID: 37196645
[TBL] [Abstract][Full Text] [Related]
11. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
[TBL] [Abstract][Full Text] [Related]
15. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using ¹³¹I-whole body scans to identify metastases of differentiated thyroid cancer.
Liepe K
Int J Surg; 2015 Apr; 16(Pt A):107-112. PubMed ID: 25771100
[TBL] [Abstract][Full Text] [Related]
19. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]